(Photo Courtesy: www.moneycontrol.com/)
Erected in 2015, Indoor Biotechnologies India (IBI) was founded by Dr Martin Chapman (62), serving as the president and CEO of this Bangalore-based start-up, along with executive directors Dr James Hindley (32), and Dr Sivasankar Baalasubramanian (Shiv, 43), all of whom are highly-qualified scientists from the academia.
Indoor focuses in manufacturing biologics for allergy and asthma. It manufactures highly purified allergens for allergy research and diagnostics, and is internationally recognized for research on allergen structure, function and immune recognition. It functions with a mission to improve the quality of life of patients with allergies and asthma.
It offers products and services for indoor air quality and environmental sciences, both for research and consumer usage.
The company assesses environmental exposure to allergens at home, workplace, schools and commercial buildings.
The start-up also caters to pharmaceutical and biotechnology companies which are involved in food allergy safety.